IP Library Granted Patent US 8,017,339
Granted Patent B2
US 8,017,339 · App. 12/802,862 · Granted Sep 13, 2011

Compositions and kits for recombinase polymerase amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,339
App. No.
12/802,862
Granted
Sep 13, 2011
Kind
B2
Abstract

This disclosure describes three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length.

Claims (65)

1. A composition comprising:

(1) at least one recombinase;

(2) at least one single stranded DNA binding protein;

(3) at least one DNA polymerase;

(4) dNTPs or a mixture of dNTPs and ddNTPs;

(5) a crowding agent;

(6) a buffer;

(7) a reducing agent;

(8) ATP or ATP analog;

(9) at least one recombinase loading protein;

(10) a first primer and optionally a second primer; and

(11) a target nucleic acid molecule.

2. The composition of claim 1 wherein said recombinase is selected from the group consisting of uvsX, recA and combinations thereof.

3. The composition of claim 1 wherein said single stranded DNA binding protein is selected from the group consisting of E. coli SSB, T4 gp32, and combinations thereof.

4. The composition of claim 1 wherein the at least one DNA polymerase includes at least one DNA polymerase which lacks 3′-5′ exonuclease activity.

5. The composition of claim 1 wherein said at least one DNA polymerase comprises a DNA polymerase with strand displacing properties.

6. The composition of claim 1 wherein said crowding agent comprises polyethylene glycol, dextran and/or ficoll.

7. The composition of claim 6 wherein said crowding agent comprises polyethylene glycol at a concentration between 1 to 12% of a weight or a volume of the composition.

8. The composition of claim 6 wherein said polyethylene glycol is selected from the group consisting of PEG1450, PEG3000, PEG8000, PEG10000, PEG compound (molecular weight 15,000 to 20,000), and combinations thereof.

9. The composition of claim 1 wherein said at least one recombinase loading protein is selected from the group consisting of T4_uvsY, E. coli real), E. coli recR and combinations thereof.

10. The composition of claim 1 , wherein:

(1) the at least one recombinase comprises a uvsX recombinase at a concentration of between 0.2 to 12 μM;

(2) the at least one single stranded DNA binding protein comprises a gp32 single stranded DNA binding protein at a concentration between 1 to 30 μM;

(3) the at least one DNA polymerase comprises a T4 gp43 DNA polymerase or Bsu polymerase at a concentration between 500 to 5000 units per ml;

(4) the dNTPs or a mixture of dNTPs and ddNTPs are present in the composition at a concentration of between 1-300 μM;

(5) the crowding agent comprises polyethylene glycol at a concentration of between 1% to 12% by weight or by volume;

(6) the buffer comprises Tris-acetate buffer at a concentration of between 1 mM to 60 mM;

(7) the reducing agent comprises dithiothreitol (DTT) at a concentration of between 1 mM-10 mM;

(8) the ATP or ATP analog comprises ATP at a concentration of between 1 mM-10 mM;

(9) the at least one recombinase loading protein comprises uvsY at a concentration of between 0.2 μM-8 μM;

(10) said primers are at a concentration of between 50 nM to 1 μM; and

(11) the target nucleic acid molecule is present in the composition in at least one copy.

11. A dry composition comprising:

(1) at least one recombinase;

(2) at least one single stranded DNA binding protein;

(3) at least one DNA polymerase;

(4) dNTPs or a mixture of dNTPs and ddNTPs

(5) a reducing agent;

(6) ATP or ATP analog;

(7) at least one recombinase loading protein;

(8) a first primer and optionally a second primer; and

(9) a crowding agent.

12. The dry composition of claim 11 , wherein:

(1) the at least one recombinase comprises a uvsX recombinase;

(2) the at least one single stranded DNA binding protein comprises a gp32 single stranded DNA binding protein;

(3) the at least one DNA polymerase comprises a Bsu polymerase or T4 polymerase;

(4) the dNTPs or a mixture of dNTPs and ddNTPs comprises dNTPs;

(5) the reducing gent comprises dithiothreitol (DTT);

(6) the at least one recombinase loading protein comprises a uvsY recombinase loading protein; and wherein the dry composition further comprises

(7) potassium acetate;

(8) magnesium acetate;

(9) phosphocreatine; and

(10) creatine kinase.

13. The dry composition of claim 11 , wherein the crowding agent comprises polyethylene glycol.

14. The dry composition of claim 12 , wherein the crowding agent comprises polyethylene glycol.

15. A kit comprising:

(1) at least one recombinase;

(2) at least one single stranded DNA binding protein;

(3) at least one DNA polymerase;

(4) a crowding agent;

(5) at least one recombinase loading protein.

16. The kit of claim 15 , further comprising dNTPs or a mixture of dNTPs and ddNTPs.

17. The kit of claim 15 , further comprising a buffer, a reducing agent, and/or ATP or ATP analog.

18. The kit of claim 15 , further comprising a first primer and optionally a second primer.

19. The kit of claim 15 , wherein the crowding agent comprises polyethylene glycol.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
CHANGE OF NAME Recorded Sep 30, 2010
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 025066/0515 →
CERTIFICATE OF MERGER Recorded Sep 30, 2010
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 025066/0614 →
CHANGE OF NAME Recorded Sep 30, 2010
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO, INC.
Reel/Frame 025066/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: PIEPENBURG, OLAF; WILLIAMS, COLIN H.; ARMES, NIALL A.; STEMPLE, DEREK L.
To: ASM SCIENTIFIC, INC.
Reel/Frame 025063/0667 →